SGMO Stock Overview
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation.
Sangamo Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.31|
|52 Week High||US$12.83|
|52 Week Low||US$3.12|
|1 Month Change||21.75%|
|3 Month Change||-25.04%|
|1 Year Change||-64.14%|
|3 Year Change||-59.98%|
|5 Year Change||-51.02%|
|Change since IPO||-71.39%|
Recent News & Updates
Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates
One thing we could say about the analysts on Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) - they aren't optimistic...
|SGMO||US Biotechs||US Market|
Return vs Industry: SGMO underperformed the US Biotechs industry which returned -24.4% over the past year.
Return vs Market: SGMO underperformed the US Market which returned -18.5% over the past year.
|SGMO Average Weekly Movement||12.0%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: SGMO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: SGMO's weekly volatility (12%) has been stable over the past year.
About the Company
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease.
Sangamo Therapeutics Fundamentals Summary
|SGMO fundamental statistics|
Is SGMO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SGMO income statement (TTM)|
|Cost of Revenue||US$232.97m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.20|
|Net Profit Margin||-156.53%|
How did SGMO perform over the long term?See historical performance and comparison
Is SGMO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SGMO?
Other financial metrics that can be useful for relative valuation.
|What is SGMO's n/a Ratio?|
Price to Sales Ratio vs Peers
How does SGMO's PS Ratio compare to its peers?
|SGMO PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
Price-To-Sales vs Peers: SGMO is good value based on its Price-To-Sales Ratio (5.6x) compared to the peer average (114.7x).
Price to Earnings Ratio vs Industry
How does SGMO's PE Ratio compare vs other companies in the U.S. Biotechs Industry?
Price-To-Sales vs Industry: SGMO is good value based on its Price-To-Sales Ratio (5.6x) compared to the US Biotechs industry average (14.1x)
Price to Sales Ratio vs Fair Ratio
What is SGMO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||5.6x|
|Fair PS Ratio||1.3x|
Price-To-Sales vs Fair Ratio: SGMO is expensive based on its Price-To-Sales Ratio (5.6x) compared to the estimated Fair Price-To-Sales Ratio (1.3x).
Share Price vs Fair Value
What is the Fair Price of SGMO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SGMO ($4.31) is trading below our estimate of fair value ($142.02)
Significantly Below Fair Value: SGMO is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SGMO's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Sangamo Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SGMO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SGMO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SGMO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SGMO's revenue (32.5% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: SGMO's revenue (32.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SGMO's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Sangamo Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SGMO is currently unprofitable.
Growing Profit Margin: SGMO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SGMO is unprofitable, and losses have increased over the past 5 years at a rate of 24% per year.
Accelerating Growth: Unable to compare SGMO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SGMO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: SGMO has a negative Return on Equity (-52.71%), as it is currently unprofitable.
Discover strong past performing companies
How is Sangamo Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: SGMO's short term assets ($340.1M) exceed its short term liabilities ($118.5M).
Long Term Liabilities: SGMO's short term assets ($340.1M) exceed its long term liabilities ($201.3M).
Debt to Equity History and Analysis
Debt Level: SGMO is debt free.
Reducing Debt: SGMO has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SGMO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SGMO has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 15.6% each year.
Discover healthy companies
What is Sangamo Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SGMO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SGMO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SGMO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SGMO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SGMO has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sandy Macrae (58 yo)
Dr. Alexander D. Macrae, also known as Sandy, M.B., Ch B, Ph D., MRCP, serves as an Independent Non-Executive Director of 4D pharma plc since August 27, 2019.Dr. Macrae has been the Chief Executive Office...
CEO Compensation Analysis
Compensation vs Market: Sandy's total compensation ($USD4.74M) is about average for companies of similar size in the US market ($USD4.05M).
Compensation vs Earnings: Sandy's compensation has increased whilst the company is unprofitable.
Experienced Management: SGMO's management team is considered experienced (2.8 years average tenure).
Experienced Board: SGMO's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SGMO insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Sangamo Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Sangamo Therapeutics, Inc.
- Ticker: SGMO
- Exchange: NasdaqGS
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$632.222m
- Shares outstanding: 146.69m
- Website: https://www.sangamo.com
Number of Employees
- Sangamo Therapeutics, Inc.
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.